What RNA Aptamers Are and Why They Matter Now
RNA aptamers are single-stranded oligonucleotides selected via iterative in vitro evolution to bind molecular targets with antibody-like affinity and specificity, yet with significantly lower manufacturing complexity and immunogenicity. Unlike monoclonal antibodies, aptamers are chemically synthesised, enabling precise control over structure, modification, and conjugation — properties that are now being exploited to solve some of the hardest problems in drug delivery and target engagement.
The foundational selection mechanism — SELEX (Systematic Evolution of Ligands by EXponential Enrichment) — involves iterative screening of randomised RNA libraries against a protein target, progressively enriching sequences with the highest binding affinity. According to WIPO, nucleic acid therapeutics represent one of the fastest-growing patent categories in biopharmaceuticals globally, and aptamers sit at the intersection of this trend with the broader RNA medicine revolution.
The therapeutic appeal of RNA aptamers rests on three core properties: their capacity to fold into precise three-dimensional structures (hairpins, G-quadruplexes, pseudoknots) that occupy protein active sites or protein-protein interaction interfaces; their ability to be chemically modified for in vivo stability; and their modularity as targeting moieties in conjugate architectures. SomaLogic Operating Co. (US20210246446A1) describes foundational SELEX refinements incorporating negative selection steps and modified nucleotide bases to improve selectivity — work that underpins much of the platform-level innovation represented in this dataset.
Cell-SELEX is a variant of the SELEX process in which aptamer selection is performed against intact living cells rather than purified protein targets. This approach, used by the University of Florida Research Foundation (US20240165270A1), enables identification of aptamers that bind cell-surface receptors and undergo receptor-mediated endocytosis — making them capable of delivering therapeutic cargos directly into target cells without prior knowledge of the specific receptor structure.
RNA aptamers are single-stranded oligonucleotides selected via SELEX (Systematic Evolution of Ligands by EXponential Enrichment) to bind molecular targets with antibody-like affinity and specificity, but with lower manufacturing complexity and immunogenicity than monoclonal antibodies.
A Filing Surge: 2023–2024 as the Inflection Point
Among the 20 unique patent records in this dataset spanning 2021 to January 2025, 14 of 20 were published in 2023–2024, indicating a pronounced acceleration in RNA aptamer therapeutic filings during this period. This concentration is not merely a data artefact — it reflects a genuine maturation of the field, as earlier platform-level work on SELEX methodology and chemical modification has now translated into a wave of disease-specific therapeutic applications.
The 2021 records — from SomaLogic Operating Co. (US20210246446A1) and Novartis AG (US20210355472A1) — represent foundational platform and therapeutic target work respectively. The 2022 cohort, from Technion Research and Development Foundation Limited, Aptamer Group Limited, and Guangdong Provincial People’s Hospital, consolidates core therapeutic targeting strategies. The 2023 cohort introduces more sophisticated conjugate formats, with Duke University filing two records on aptamer-siRNA chimeras (US20230338441A1) and CD4-targeted T cell delivery (US20230203479A1).
The 2024–2025 cohort — comprising 9 records — reflects the current innovation frontier: blood-brain barrier traversal (University of Florida, US20240182898A1), lipid nanoparticle-aptamer hybrids (Massachusetts Institute of Technology, US20240368586A1), immune checkpoint blockade (National Cancer Institute, US20240058473A1), and reversible anticoagulation (Emory University, US20240018030A1). The newest record — from the University of North Carolina at Chapel Hill (US20250019709A1, January 2025) — targets Midkine, a pleiotropic oncofetal growth factor, signalling expansion into less-explored oncology targets.
“14 of 20 RNA aptamer therapeutic patent records in this dataset were published in 2023–2024 — a concentration that reflects genuine field maturation, as platform-level SELEX work has translated into a wave of disease-specific applications.”
Track RNA aptamer patent filings in real time across all jurisdictions with PatSnap Eureka’s AI-powered search.
Explore Patent Data in PatSnap Eureka →Among 20 RNA aptamer therapeutic patent records published between 2021 and January 2025, 14 were published in 2023–2024, with 2024 representing the largest single-year cohort at 8 records, indicating a pronounced acceleration in the field.
Four Technology Clusters Shaping the RNA Aptamer Field
The patent dataset organises into four distinct technology clusters, each addressing a different dimension of the RNA aptamer therapeutic challenge: direct target antagonism, conjugate-mediated payload delivery, chemical modification for in vivo stability, and cell-internalising or barrier-crossing delivery. These clusters are not mutually exclusive — the most advanced filings combine elements from multiple clusters.
Cluster 1: Direct Target Antagonism
The most established approach involves aptamers that directly bind and functionally block disease-relevant proteins, mimicking monoclonal antibody mechanisms. These aptamers fold into three-dimensional structures — hairpins, G-quadruplexes, pseudoknots — that occupy protein active sites or protein-protein interaction interfaces. Novartis AG’s anti-TNF-alpha aptamers (US20210355472A1) represent this approach applied to inflammatory disease, while the National Cancer Institute’s anti-PD-L1 aptamers (US20240058473A1) demonstrate that RNA aptamers can achieve comparable or superior blocking activity to monoclonal antibodies targeting the PD-1/PD-L1 immune checkpoint. Archemix Corp.’s anti-VEGF aptamers (US20240182905A1) build on the precedent of pegaptanib (Macugen) — the first FDA-approved aptamer therapeutic — extending the anti-angiogenic approach with next-generation specificity for VEGF isoforms, as documented by the FDA.
Cluster 2: Aptamer-Payload Conjugate Architectures
A rapidly growing cluster involves aptamers functioning as targeting moieties in conjugate formats — linked to siRNA, small molecules, chemotherapeutics, or delivered via nanoparticles. These architectures separate targeting specificity from therapeutic payload function, enabling modular design. Duke University’s aptamer-siRNA chimeras (AsiCs, US20230338441A1) direct siRNA to specific cell populations expressing target surface receptors, with applications in cancer treatment, antiviral therapy, and immune modulation. Beijing Institute of Technology’s aptamer-drug conjugates (ApDCs, US20240269297A1) select aptamers against cancer-specific cell surface markers to achieve selective cytotoxic drug delivery. Massachusetts Institute of Technology’s aptamer-conjugated lipid nanoparticle (LNP) formulations (US20240368586A1) extend this architecture to delivery of mRNA, siRNA, and CRISPR components — representing a convergence of two major nucleic acid medicine platforms.
Cluster 3: Chemical Modification & Pharmacokinetic Engineering
A foundational cluster addresses the intrinsic limitations of RNA in vivo — nuclease degradation, renal clearance, and off-target immunostimulation — through systematic chemical engineering of the aptamer backbone and termini. Archemix Corp. (US20240026351A1) describes in vivo-compatible modifications including 2′-fluoro, 2′-O-methyl, and phosphorothioate substitutions to enhance nuclease resistance and pharmacokinetic properties. Aptamer Group Limited (US20220370614A1) extends this with PEGylation to reduce renal clearance, locked nucleic acids (LNAs), and non-natural nucleotide analogs to increase serum half-life and improve tissue distribution. These modifications are increasingly standard across the field, as documented in the broader nucleic acid therapeutics literature reviewed by Nature.
Cluster 4: Cell-Internalising & Barrier-Crossing Aptamers
An emerging cluster focuses on aptamers capable of active cellular internalisation via receptor-mediated endocytosis and crossing biological barriers such as the blood-brain barrier — enabling delivery to previously inaccessible tissue compartments. The University of Florida Research Foundation’s anti-TfR1 aptamers (US20240182898A1) are designed to traverse the blood-brain barrier and deliver therapeutic payloads including siRNA and other nucleic acid-based therapeutics across it. The same institution’s cell-internalising aptamers (US20240165270A1) are selected using cell-SELEX against live cancer cell lines, enabling intracellular delivery of siRNA, miRNA, and small molecule drugs. Duke University’s anti-CD4 aptamers (US20230203479A1) enable targeted delivery of siRNA and gene silencing agents specifically to CD4+ T cells.
The most advanced RNA aptamer filings in this dataset combine elements from multiple clusters — for example, Massachusetts Institute of Technology’s aptamer-conjugated LNP platform (US20240368586A1) integrates Cluster 2 (conjugate architecture), Cluster 3 (chemical modification), and Cluster 4 (targeted delivery) into a single therapeutic system capable of delivering mRNA, siRNA, and CRISPR components to specific cell types.
RNA aptamer therapeutic innovations organise into four technology clusters: direct target antagonism, aptamer-payload conjugate architectures (including aptamer-siRNA chimeras and aptamer-drug conjugates), chemical modification for pharmacokinetic engineering, and cell-internalising or barrier-crossing delivery systems.
Application Domains: Oncology Leads, But the Field Is Broadening
Oncology is the largest application domain in this dataset, representing approximately 10 of 20 patent records, covering solid tumours and haematological malignancies across a diverse range of molecular targets. Beyond oncology, the dataset reveals significant activity in inflammatory and autoimmune disease, cardiovascular and haemostasis, CNS drug delivery, and infectious disease — a breadth that distinguishes the current wave of RNA aptamer development from earlier, more narrowly focused efforts.
Oncology: Convergence with Immuno-Oncology
Oncology targets in this dataset include EpCAM (Guangdong Provincial People’s Hospital, US11471536B2), PSMA for prostate cancer (Technion Research and Development Foundation Limited, US20220401490A1), Midkine — a pleiotropic oncofetal growth factor — (University of North Carolina at Chapel Hill, US20250019709A1), and the immune checkpoint protein TIGIT (Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, US20240279648A1). The National Cancer Institute’s anti-PD-L1 aptamers (US20240058473A1) demonstrate direct convergence with immune checkpoint blockade — one of the most validated oncology treatment paradigms, as tracked by NIH. Aptamer-drug conjugates from Beijing Institute of Technology (US20240269297A1) and cell-internalising aptamers from the University of Florida (US20240165270A1) address the challenge of selective cytotoxic payload delivery to tumour cells.
Inflammatory & Autoimmune Disease
Novartis AG’s anti-TNF-alpha aptamers (US20210355472A1) extend a validated antibody biology — anti-TNF biologics are among the best-selling drug classes globally — into nucleic acid format, with enhanced serum stability and reduced immunogenicity. Aptamer Group Limited’s complement inhibitors targeting C3 and C5 (US20240018517A1) address age-related macular degeneration (AMD) and paroxysmal nocturnal haemoglobinuria (PNH). Duke University’s anti-CD4 aptamers (US20230203479A1) enable selective gene silencing in pathogenic CD4+ T cell populations for autoimmune conditions including HIV infection and other T cell-mediated diseases.
Cardiovascular & Haemostasis
Emory University’s thrombin-targeting aptamers (US20240018030A1) introduce a clinically significant design feature: antidote counterparts that allow reversible anticoagulation. This reversibility — the ability to rapidly neutralise the aptamer’s anticoagulant effect — represents a meaningful therapeutic advantage over traditional anticoagulants and is applicable to thrombotic disorders, atrial fibrillation, and perioperative anticoagulation management.
Infectious Disease
The Chinese University of Hong Kong’s SARS-CoV-2-targeting aptamers (US20230340474A1) describe RNA and DNA aptamers binding to the spike protein receptor binding domain (RBD), N protein, and S2 subunit, with applications in both antiviral therapy and diagnostics. This record illustrates the rapid responsiveness of the aptamer field to emerging infectious disease threats — SELEX campaigns against novel viral targets can be conducted in weeks.
Map the full RNA aptamer competitive landscape across assignees, jurisdictions, and therapeutic areas with PatSnap Eureka.
Analyse Aptamer Patents in PatSnap Eureka →Emerging Directions and the Frontier of RNA Aptamer Innovation
The 2024–2025 cohort of filings reveals several emerging directions that are likely to define the next phase of RNA aptamer therapeutic development. These include the integration of aptamers with lipid nanoparticle delivery systems, expansion into less-explored oncology targets, and the design of reversible or antidote-controllable aptamer therapeutics.
Aptamer-LNP Hybrid Platforms
Massachusetts Institute of Technology’s aptamer-conjugated LNP formulations (US20240368586A1) represent a convergence of two major nucleic acid medicine platforms. By decorating the surface of lipid nanoparticles with aptamers as targeting moieties, this approach combines the efficient nucleic acid encapsulation and endosomal escape capabilities of LNPs with the precise cell-type specificity of aptamers. Applications described include cancer treatment, genetic disorders, and immunotherapy — with payloads spanning mRNA, siRNA, and CRISPR components. This convergence is consistent with broader trends in nucleic acid delivery documented by NIH and the IEEE Engineering in Medicine and Biology Society.
CNS Drug Delivery via Receptor-Mediated Transcytosis
The blood-brain barrier remains one of the most significant obstacles in CNS drug development. The University of Florida Research Foundation’s anti-TfR1 aptamers (US20240182898A1) exploit the transferrin receptor’s natural transcytosis pathway to carry therapeutic payloads — including siRNA and other nucleic acid-based therapeutics — across the BBB. This approach, if validated in clinical settings, could open RNA aptamer therapeutics to a broad range of neurological conditions that are currently inaccessible to large-molecule drugs.
Reversible & Antidote-Controlled Aptamer Therapeutics
Emory University’s thrombin aptamers with antidote counterparts (US20240018030A1) introduce a design principle with broad applicability beyond anticoagulation: the concept of an aptamer therapeutic whose activity can be rapidly reversed by administration of a complementary oligonucleotide. This controllability addresses one of the key clinical concerns around nucleic acid therapeutics — the inability to rapidly terminate drug action in the event of adverse effects — and may prove particularly valuable in perioperative and emergency medicine settings.
Expansion into Novel Oncology Targets
The University of North Carolina at Chapel Hill’s Midkine-targeting aptamers (US20250019709A1) and the Guangzhou Institutes of Biomedicine and Health’s TIGIT-targeting aptamers (US20240279648A1) signal expansion beyond the most-studied oncology targets into the next tier of tumour biology. Midkine is a heparin-binding growth factor overexpressed in a wide range of human cancers, while TIGIT is an emerging immune checkpoint with significant interest as a combination immunotherapy partner. Both targets reflect the field’s increasing confidence in applying aptamer selection to complex, clinically validated but less-explored molecular targets.
RNA aptamers targeting transferrin receptor 1 (TfR1), as described in a 2024 patent from the University of Florida Research Foundation (US20240182898A1), are designed to traverse the blood-brain barrier via receptor-mediated transcytosis and deliver therapeutic payloads including siRNA to the CNS — representing an emerging approach to RNA therapeutics delivery for neurological conditions.
Emory University’s 2024 patent (US20240018030A1) describes RNA aptamers targeting thrombin for anticoagulation therapy that include antidote counterparts enabling reversible anticoagulation — a design feature that allows rapid neutralisation of the aptamer’s activity, representing a therapeutic advantage over traditional anticoagulants.
Across all five application domains and four technology clusters, the assignee landscape is notably diverse — spanning major research universities (University of Florida, Duke University, MIT, Emory University, University of North Carolina), established pharmaceutical companies (Novartis AG), specialist aptamer companies (Archemix Corp., Aptamer Group Limited, SomaLogic Operating Co.), national research institutes (National Cancer Institute), and Chinese academic institutions (Guangdong Provincial People’s Hospital, Guangzhou Institutes of Biomedicine and Health, Beijing Institute of Technology). This diversity suggests a field that has not yet consolidated around dominant commercial players, with significant opportunity for both academic spinouts and established pharma to define leadership positions. Patent landscape analysis tools such as PatSnap’s IP Intelligence platform and PatSnap Eureka can help R&D teams map white spaces and monitor competitor activity across this rapidly evolving space.